Kymera
interim safety data summary patients at dose level all patients heavily prior lines solid tumor no no treatment related no aes leading to discontinuation | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2022
Slide
11 of 63
Similar slides by Kymera
See diffirences between slides (animation)
Results
December 2022
interim safety data summary | Kymera
Related slides by other companies
Ocuphire Pharma
Investor Presentation
November 2023
summary to have a clinically meaningful impact on slowing or preventing progression to reduce likelihood of vision loss in diabetic patients owing | Ocuphire Pharma
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
Houlihan Lokey
Investment Banking
December 2022
table of contents executive summary selected updates since prior discussion materials financial analyses appendices | Houlihan Lokey
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io